CAMP4 Therapeutics competitorsClear all

CAMP4 Therapeutics's top competitors include Oxford BioTherapeutics, MicrofluidX and Nouscom.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
CAMP4 Therapeutics
CAMP4 Therapeutics
CAMP4 Therapeutics is a biotechnology company.
Oxford BioTherapeutics
Oxford BioTherapeutics
Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.
MicrofluidX
MicrofluidX
MicrofluidX is a company that develops cell bioprocessing technology.
Nouscom
Nouscom
Nouscom is a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.
Founding Date
Founding Date
2016
Founding Date
2004
Founding Date
2018
Founding Date
2015
Type
Type
Private
Type
Private
Type
Private
Type
Private
Tags
Locations
Locations
Cambridge, US HQ
Locations
Milton, GB HQ
San Jose, US
Locations
HQ
Locations
Basel, CH HQ
Roma, IT
Employees
Employees
51
Employees
28
Employees
5
Employees
33
Alexa Website Rank
Alexa Website Rank
235805
Alexa Website Rank
N/A
Alexa Website Rank
N/A
Alexa Website Rank
245902

Funding

Latest funding round
Latest funding round
$ 30m (over 3 years ago)
Latest funding round
$ 10m (about 6 years ago)
Latest funding round
$ 1.7m (over 1 year ago)
Latest funding round
$ 49m (almost 4 years ago)
Total funding raised
Total funding raised
$ 30m
Total funding raised
$ 21.6m
Total funding raised
$ 1.7m
Total funding raised
$ 62.6m
For sources of this data, please see the company profile

View company profiles

Oxford BioTherapeutics
HQ
Milton, GB
Employees
28

Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.

View company
MicrofluidX
HQ
Employees
5

MicrofluidX is a company that develops cell bioprocessing technology.

View company
Nouscom
HQ
Basel, CH
Employees
33

Nouscom is a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.

View company